



## Financial Tear Sheet

### Corporate Profile

Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Our proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Our lead programs address inflammatory diseases, genetic disorders and oncology.

### Primary IR Contact

MacDougall Biomedical  
Communications  
Karen Sharma

**Phone:** 781-235-3060

**E-mail:**

[ksharma@macbiocom.com](mailto:ksharma@macbiocom.com)

### Recent Headlines & Events

11/14/17 - 2:44 p.m.

[Exicure, Inc. Reports Third Quarter 2017  
Financial Results and Provides Business  
Update](#)

There are currently no events scheduled.

11/06/17 - 2:43 p.m.

[Exicure, Inc. Closes Additional \\$11.2  
Million in Private Financing to Advance  
its Gene Regulatory and  
Immunotherapeutic Programs](#)

09/27/17 - 3:42 p.m.

[Exicure, Inc. Successfully Completes  
Reverse Merger and Closes \\$20 Million  
Private Placement](#)

### SEC Filings

Filing Date	Form
11/28/17	<a href="#"><u>S-1</u></a>
11/14/17	<a href="#"><u>10-Q</u></a>

11/14/17

8-K

11/07/17

8-K/A

Data provided by Nasdaq. Minimum 15 minutes delayed.